Visualization of five hyperplastic parathyroid glands using 99mTc-sestamibi scintigraphy in a patient with chronic renal failure.
Explore the source record for details and available documents.
Humans↗
Biomedical subjects
Gonca Bural
Publications and source records attributed to Gonca Bural.
Fluorodeoxyglucose-PET in the management of malignant melanoma.
FDG-PET is of limited use in patients with early-stage disease without nodal or distant metastases (stage I-II), because sentinel node biopsy is much more sensitive in detecting microscopic lymph node metastases. Because of the high tumor-to-background ratio, FDG-PET can highlight metastases at unusual sites that are easily missed with conventional imaging modalities. PET has been shown to have a strong role in detecting metastatic disease. FDG-PET is more sensitive than CT for detecting metastatic lesions in skin, lymph nodes, and abdomen, but CT is equivalent to or more sensitive than FDG-PET for detecting small pulmonary lesions. FDG-PET identifies the location and number of metastatic lesions in stage III and IV disease and therefore is important for surgical planning. Most of the false-negative FDG-PET results are caused by micrometastases and lesion smaller than 10 mm. Postsurgical inflammation, other inflammatory lesions, and some benign tumors cause some false-positive FDG-PET results.
Fluorodeoxyglucose F18↗
Normal variants in [18F]-fluorodeoxyglucose PET imaging.
The number of fluorodeoxyglucose PET applications is increasing. In the process of reading fluorodeoxyglucose-PET scans, nuclear medicine physicians encounter a wide variety of normal findings, which must be recognized to determine the best management for patients. It is important to recognize and understand normal variants to avoid misinterpretation of more serious pathology. This article reviews different patterns of physiologic fluorodeoxyglucose uptake including changes with age.
Aging↗